PPARγ and Its Agonists in Chronic Kidney Disease

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a progressive global health issue with major risk factors including obesity, diabetes, and cardiovascular diseases.
• Understanding CKD pathogenesis is crucial for developing new therapeutic strategies.
• Peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor, plays significant roles in metabolic regulation and is expressed in kidney cells.

Purpose of the Study:

• To systematically review the function of PPARγ in the context of CKD.
• To assess the benefits and limitations of PPARγ agonists in clinical applications for CKD.
• To explore novel therapeutic strategies targeting PPARγ for CKD management.

Main Methods:

• Systematic literature review of studies investigating PPARγ.
• Analysis of preclinical (cell and animal models) and clinical data on PPARγ function in the kidney.
• Evaluation of the efficacy and side effects of PPARγ agonists, such as thiazolidinediones (TZDs).

Main Results:

• PPARγ agonists, like TZDs, have shown protective effects in diseases associated with CKD risk factors and exhibit functions in kidney cells including energy metabolism, proliferation, and inflammation suppression.
• Despite potential benefits, existing PPARγ agonists have demonstrated significant renal side effects, limiting their use in CKD treatment.
• The precise roles and therapeutic potential of PPARγ in CKD require further investigation.

Conclusions:

• PPARγ is a key player in kidney physiology and pathology, offering potential therapeutic targets for CKD.
• Current PPARγ agonists face limitations due to renal side effects, necessitating the development of more targeted or safer therapeutic approaches.
• Further research is needed to fully elucidate PPARγ's role in CKD and optimize its clinical application.